Influence of a Dietary Supplement as Treatment of Migraine in Children and Adolescents

Study for Documentation of the Influence of a Specific Dietary Supplement Treatment of Migraine in Children and Adolescents

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01010711

Enrollment

Registered

2009-11-10

Start date

2009-11-30

Completion date

2011-04-30

Last updated

2010-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Migraine

Keywords

migraine, children, dietary supplement, q10, prevention

Brief summary

Migraine in children and adolescents can be associated with low serum levels of coenzyme q10, the key-enzyme of mitochondrial energy production.During migraine attacks inflammation is an important issue. Based on a double-blind placebo-controlled trial with coenzyme q10 in adults it is hypothesized that daily supplementation of coenzyme q10 as well as different antioxidative phytochemicals (from berries) and specific minerals and vitamins are able to reduce the days with migraine as primary parameter (open clinical trial).

Detailed description

Children or adolescents with migraine and both parents are informed in detail about the study.Probands are advised to fill in a special childrens´ diary for migraine daily. After a 4 week-run-in period they start to take the dietary supplement (powder to be dissolved in water)plus a capsule with omega-3-fatty acids from fish oil for 12 weeks daily. Afterwards there is a follow-up without supplement treatment for another 12 weeks.76 participants will be included in the trial for statistical evaluation.

Interventions

DIETARY_SUPPLEMENTMigra 3

powder containing coenzyme q10, blueberries, black current, vitamins, magnesium,trace elements

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

8 Years to 17 Years

Healthy volunteers

Yes

Inclusion criteria

* at least 3 days of migraine per month

Exclusion criteria

* not able to communicate in german or english language * any disease that forbids the participation in the trial according to the investigators assessment * pregnancy * no willingness to participate in the trial * known allergy to fish or soya

Design outcomes

Primary

Measure	Time frame
number of days with headache before and after 12 weeks of daily treatment with a migraine specific dietary supplement	headaches before and after 12 weeks of treatment

Secondary

Measure	Time frame
frequency, duration and intensity of the migraine	before and after 12 weeks of treatment

Countries

Germany

Contacts

Primary ContactCharly Gaul, MD

Charly.Gaul@gmx.de0049-201-43696-0

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026